The DOI matches its OpenAlex record.
CLINICAL PERSPECTIVE: Acromegaly and Cancer: Not a Problem?
Abstract
Acromegaly is usually caused by a GH-secreting pituitary adenoma. Somatic growth and metabolic dysfunction occur subsequent to unrestrained GH secretion and elevated insulin-like growth factor (IGF)-I and IGF-binding protein (IGFBP)-3 levels (1) (Fig 1). Classic clinical features of acromegaly include acral overgrowth, sweating, headaches, menstrual disturbances, and glucose intolerance (Table 1) (2). Well-documented clinical risks of long-term tissue exposure to uncontrolled GH hypersecretion include cardiac disease and hypertension, diabetes, respiratory disorders, joint disease, and neuropathy (Table 2) (3). The degree of risk for malignancy in these patients is unresolved; and acromegaly, representing an experiment of nature, could answer the question of whether or not elevated GH and IGF levels provide a permissive growth advantage for neoplasms, resulting in more aggressive malignant disease and/or increased cancer-associated mortality (4). Analysis of the determinants for mortality outcome in acromegaly indicates that approximately 60% of patients succumb to cardiovascular disease; 25% from respiratory disease; and in 15% of patients, the cause of death is attributed to malignancy (Table 2). Nevertheless, absolute circulating GH values seem to constitute the most significant single determinant of survival, regardless of the cause of death (5–14). Several recent compelling studies support the critical role of GH, suggesting that GH control is associated with reversal of adverse mortality rates, regardless of the nature of associated comorbidity (13). Thus, suppression of GH to less than 1 ng/mL, during an oral glucose tolerance test, and normalization of IGF-I levels portend a favorable mortality outcome (15).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management
Colao, A., Ferone, D., Marzullo, P., & Lombardi, G. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0022 · Cited by 1,309
Melmed, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062453 · Cited by 1,160
Self-citationMortality in Patients with Pituitary Disease
Sherlock, M., Ayuk, J., Tomlinson, J. W., Toogood, A. A., Aragon-Alonso, A., Sheppard, M. C., Bates, A. S., & Stewart, P. M. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0033 · Cited by 392
Mestron, A., Webb, S., Astorga, R., Benito, P., Catala, M., Gaztambide, S., Gomez, J., Halperin, I., Lucas-Morante, T., Moreno, B., et al. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510439 · Cited by 387
Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update
Gadelha, M. R., Kasuki, L., Lim, D. S. T., & Fleseriu, M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00115 · Cited by 363
Metadata
- Authors
- Melmed, S. K.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- Oxford University Press
- Published
- 2001-07-01
- Volume
- 86
- Issue
- 7
- Pages
- 2929-2934
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2022722603
- Cited by
- 196
- References
- 0
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CLINICAL PERSPECTIVE: Acromegaly and Cancer: Not a Problem? https://app.cochat.ai/papers/10.1210/jc.86.7.2929
- The paper
- Melmed, S. K. (2001). CLINICAL PERSPECTIVE: Acromegaly and Cancer: Not a Problem? The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.86.7.2929
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.